PortfoliosLab logoPortfoliosLab logo
CPRX vs. BMRN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CPRX vs. BMRN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Catalyst Pharmaceuticals, Inc. (CPRX) and BioMarin Pharmaceutical Inc. (BMRN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CPRX achieves a 33.98% return, which is significantly higher than BMRN's -10.28% return. Over the past 10 years, CPRX has outperformed BMRN with an annualized return of 48.23%, while BMRN has yielded a comparatively lower -5.10% annualized return.


CPRX

1D
0.00%
1M
8.80%
YTD
33.98%
6M
38.24%
1Y
25.58%
3Y*
39.37%
5Y*
41.56%
10Y*
48.23%

BMRN

1D
-3.11%
1M
-1.37%
YTD
-10.28%
6M
-1.06%
1Y
-6.54%
3Y*
-17.03%
5Y*
-7.17%
10Y*
-5.10%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CPRX vs. BMRN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CPRX
Catalyst Pharmaceuticals, Inc.
33.98%11.84%24.15%-9.62%174.74%102.69%-10.93%95.31%-50.90%272.38%
BMRN
BioMarin Pharmaceutical Inc.
-10.28%-9.58%-31.83%-6.83%17.14%0.75%3.71%-0.70%-4.51%7.64%

Correlation

The correlation between CPRX and BMRN is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.31

Correlation (3Y)
Calculated over the trailing 3-year period

0.30

Correlation (5Y)
Calculated over the trailing 5-year period

0.37

Correlation (10Y)
Calculated over the trailing 10-year period

0.33

Correlation (All Time)
Calculated using the full available price history since Nov 9, 2006

0.23

The correlation between CPRX and BMRN shifts across timeframes, from 0.23 (all time) to 0.37 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

CPRX:

$3.97B

BMRN:

$10.54B

EPS

CPRX:

$1.74

BMRN:

$1.37

PE Ratio

CPRX:

17.97

BMRN:

38.87

PEG Ratio

CPRX:

0.32

BMRN:

2.33

PS Ratio

CPRX:

6.66

BMRN:

3.22

PB Ratio

CPRX:

3.92

BMRN:

1.70

Total Revenue (TTM)

CPRX:

$596.96M

BMRN:

$3.24B

Gross Profit (TTM)

CPRX:

$378.23M

BMRN:

$2.46B

EBITDA (TTM)

CPRX:

$313.50M

BMRN:

$439.56M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CPRX vs. BMRN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CPRX
CPRX Risk / Return Rank: 6060
Overall Rank
CPRX Sharpe Ratio Rank: 6464
Sharpe Ratio Rank
CPRX Sortino Ratio Rank: 5959
Sortino Ratio Rank
CPRX Omega Ratio Rank: 5959
Omega Ratio Rank
CPRX Calmar Ratio Rank: 6060
Calmar Ratio Rank
CPRX Martin Ratio Rank: 5757
Martin Ratio Rank

BMRN
BMRN Risk / Return Rank: 2929
Overall Rank
BMRN Sharpe Ratio Rank: 3232
Sharpe Ratio Rank
BMRN Sortino Ratio Rank: 2929
Sortino Ratio Rank
BMRN Omega Ratio Rank: 2828
Omega Ratio Rank
BMRN Calmar Ratio Rank: 2828
Calmar Ratio Rank
BMRN Martin Ratio Rank: 2626
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CPRX vs. BMRN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and BioMarin Pharmaceutical Inc. (BMRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CPRXBMRNDifference

Sharpe ratio

Return per unit of total volatility

0.76

-0.19

+0.96

Sortino ratio

Return per unit of downside risk

1.25

-0.05

+1.30

Omega ratio

Gain probability vs. loss probability

1.16

0.99

+0.17

Calmar ratio

Return relative to maximum drawdown

0.93

-0.36

+1.29

Martin ratio

Return relative to average drawdown

1.69

-0.76

+2.45

CPRX vs. BMRN - Sharpe Ratio Comparison

The current CPRX Sharpe Ratio is 0.76, which is higher than the BMRN Sharpe Ratio of -0.19. The chart below compares the historical Sharpe Ratios of CPRX and BMRN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CPRXBMRNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.76

-0.19

+0.96

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.87

-0.22

+1.09

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.80

-0.14

+0.94

Sharpe Ratio (All Time)

Calculated using the full available price history

0.09

0.11

-0.02

Drawdowns

CPRX vs. BMRN - Drawdown Comparison

The maximum CPRX drawdown since its inception was -94.25%, roughly equal to the maximum BMRN drawdown of -90.58%. Use the drawdown chart below to compare losses from any high point for CPRX and BMRN.


Loading charts...

Drawdown Indicators


CPRXBMRNDifference

Max Drawdown

Largest peak-to-trough decline

-94.25%

-90.58%

-3.67%

Max Drawdown (1Y)

Largest decline over 1 year

-27.29%

-22.49%

-4.80%

Max Drawdown (3Y)

Largest decline over 3 years

-27.29%

-49.83%

+22.54%

Max Drawdown (5Y)

Largest decline over 5 years

-45.37%

-57.64%

+12.27%

Max Drawdown (10Y)

Largest decline over 10 years

-64.87%

-62.09%

-2.78%

Current Drawdown

Current decline from peak

-0.19%

-64.25%

+64.06%

Average Drawdown

Average peak-to-trough decline

-52.06%

-45.51%

-6.55%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.95%

10.80%

+4.15%

Volatility

CPRX vs. BMRN - Volatility Comparison

The current volatility for Catalyst Pharmaceuticals, Inc. (CPRX) is 6.81%, while BioMarin Pharmaceutical Inc. (BMRN) has a volatility of 15.31%. This indicates that CPRX experiences smaller price fluctuations and is considered to be less risky than BMRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CPRXBMRNDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.81%

15.31%

-8.50%

Volatility (6M)

Calculated over the trailing 6-month period

23.82%

27.72%

-3.90%

Volatility (1Y)

Calculated over the trailing 1-year period

33.60%

34.52%

-0.92%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

47.86%

32.85%

+15.01%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

60.62%

35.51%

+25.11%

Dividends

CPRX vs. BMRN - Dividend Comparison

Neither CPRX nor BMRN has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CPRX vs. BMRN - Financials Comparison

This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M20222023202420252026
149.39M
766.21M
(CPRX) Total Revenue
(BMRN) Total Revenue
Values in USD except per share items

CPRX vs. BMRN - Profitability Comparison

The chart below illustrates the profitability comparison between Catalyst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%202220232024202520260
74.6%
Portfolio components
CPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.

BMRN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported a gross profit of 571.21M and revenue of 766.21M. Therefore, the gross margin over that period was 74.6%.

CPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.

BMRN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported an operating income of 129.64M and revenue of 766.21M, resulting in an operating margin of 16.9%.

CPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.

BMRN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported a net income of 105.53M and revenue of 766.21M, resulting in a net margin of 13.8%.


Frequently Asked Questions


CPRX and BMRN have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BMRN has higher volatility (15.31%) compared to CPRX (6.81%). In terms of maximum drawdown, CPRX dropped -94.25% vs BMRN's -90.58%.

CPRX currently has the higher Sharpe Ratio (0.76 vs -0.19), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CPRX and BMRN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer